US · OCUL · BIOTECHNOLOGY
Ocular Therapeutix, Inc. (OCUL) intrinsic value and stock valuation
$5.57as of 2026-11-21 · Mkt cap 1.86B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Ocular Therapeutix, Inc. DCF and intrinsic value
InvestorsCraft values OCUL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from OCUL’s statements →
Ocular Therapeutix, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $51.8M | $63.7M | $58.4M | $51.5M | $43.5M |
| Operating income | -$-270.02M | -$-171.78M | -$-82.38M | -$-78.65M | -$-78.04M |
| Net income | -$-265.94M | -$-193.51M | -$-80.74M | -$-71.04M | -$-6.55M |
| EPSd | -$-1.42M | -$-1.22M | -$-943.22K | -$-859.63K | -$-79.72K |
| Operating cash flow | -$-204.88M | -$-134.68M | -$-70.23M | -$-59.6M | -$-65.55M |
| Capital expenditure | -$-12.01M | -$-1.29M | -$-6.09M | -$-3.71M | -$-1.19M |
| Free cash flow | -$-216.89M | -$-135.97M | -$-76.32M | -$-63.32M | -$-66.74M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Total debt | $79.8M | $75.8M | $83.4M | $64.3M | $59M |
| Net debt | -$-657.28M | -$-316.32M | -$-112.42M | -$-38.02M | -$-105.18M |
| Total equity | $654.3M | $315.3M | $91.1M | $35.4M | $88M |
| Cash and short-term investments | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $51.8M | $63.7M | $58.4M | $51.5M | $43.5M |
| Cost of revenue | $6.57M | $5.63M | $5.28M | $4.54M | $4.41M |
| Gross profit | $45.3M | $58.1M | $53.2M | $47M | $39.1M |
| Research and development expenses | $197.1M | $127.6M | $61.1M | $53.5M | $50.1M |
| Selling, general and administrative expenses | $118.3M | $102.2M | $74.5M | $72.2M | $67.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $315.4M | $229.9M | $135.5M | $125.6M | $117.2M |
| Cost and expenses | $322M | $235.5M | $140.8M | $130.2M | $121.6M |
| Interest income | $18.4M | $20.3M | $3.98M | $800K | $30K |
| Interest expense | $11.8M | $13.6M | $11.3M | $7.02M | $6.67M |
| Depreciation and amortization | $4.32M | $3.79M | $2.98M | $2.11M | $2.42M |
| Ebitda | -$-249.78M | -$-176.14M | -$-66.42M | -$-61.91M | $2.54M |
| Operating income | -$-270.02M | -$-171.78M | -$-82.38M | -$-78.65M | -$-78.04M |
| Total other income/expenses, net | $4.08M | -$-21.73M | $1.65M | $7.62M | $71.5M |
| Income before tax | -$-265.94M | -$-193.51M | -$-80.74M | -$-71.04M | -$-6.55M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-265.94M | -$-193.51M | -$-80.74M | -$-71.04M | -$-6.55M |
| Weighted average shares outstanding | $187.2M | $158.3M | $79.8M | $76.9M | $76.4M |
| Weighted average diluted shares outstanding | $187.2M | $158.3M | $85.6M | $82.6M | $82.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $737.1M | $392.1M | $195.8M | $102.3M | $164.2M |
| Net receivables | $30.7M | $32.4M | $26.2M | $21.3M | $21.1M |
| Inventory | $3.56M | $3.04M | $2.31M | $1.97M | $1.25M |
| Total current assets | $782.1M | $441M | $232.2M | $129.6M | $191.3M |
| Property, plant and equipment, net | $24.3M | $15.3M | $18.2M | $17.9M | $11.8M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $1.61M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $25.9M | $17M | $19.8M | $19.7M | $13.6M |
| Total assets | $808.1M | $457.9M | $252.1M | $149.3M | $204.9M |
| Accounts payable | $4.15M | $4.18M | $4.39M | $5.12M | $4.59M |
| Short-term debt | $2.82M | $1.93M | $1.59M | $1.6M | $1.62M |
| Deferred revenue | $0.00 | $130K | $260K | $580K | $0.00 |
| Total current liabilities | $50.8M | $41.4M | $34.9M | $31.4M | $26.3M |
| Long-term debt | $77M | $73.9M | $81.8M | $62.7M | $57.4M |
| Deferred revenue, non-current | $14M | $14M | $14.1M | $13.4M | $13M |
| Total non-current liabilities | $102.9M | $101.2M | $126M | $82.5M | $90.6M |
| Capital lease obligations | $2.81M | $7.28M | $8.46M | $10.3M | $7.55M |
| Total liabilities | $153.8M | $142.6M | $160.9M | $113.9M | $116.9M |
| Common stock | $20K | $20K | $10K | $10K | $10K |
| Retained earnings | -$-1.16B | -$-891.08M | -$-697.58M | -$-616.84M | -$-545.8M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $654.3M | $315.3M | $91.1M | $35.4M | $88M |
| Total investments | $1.61M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $79.8M | $75.8M | $83.4M | $64.3M | $59M |
| Net debt | -$-657.28M | -$-316.32M | -$-112.42M | -$-38.02M | -$-105.18M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-265.94M | -$-193.51M | -$-80.74M | -$-71.04M | -$-6.55M |
| Depreciation and amortization | $4.32M | $3.79M | $2.98M | $2.11M | $2.42M |
| Stock-based compensation | $43.2M | $33.1M | $17.8M | $17M | $15M |
| Change in working capital | $7.71M | -$-10.23M | -$-7.41M | $1.35M | -$-2.9M |
| Accounts receivable | $1.74M | -$-6.21M | -$-4.85M | -$-190K | -$-8.88M |
| Inventory | -$-520K | -$-730K | -$-330K | -$-720K | -$-50K |
| Accounts payable | -$-890K | -$-320K | $580K | -$-620K | $1.8M |
| Net cash provided by operating activities | -$-204.88M | -$-134.68M | -$-70.23M | -$-59.6M | -$-65.55M |
| Investments in property, plant and equipment | -$-12.01M | -$-1.29M | -$-6.09M | -$-3.71M | -$-1.19M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-11.88M | -$-1.29M | -$-6.09M | -$-3.71M | -$-1.19M |
| Common stock issued | $561.7M | $316.4M | $118.1M | $940K | $980K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $561.7M | $332.1M | $169.8M | $1.45M | $2.85M |
| Net change in cash | $345M | $196.2M | $93.5M | -$-61.86M | -$-63.89M |
| Cash at end of period | $738.7M | $393.7M | $197.6M | $104.1M | $165.9M |
| Operating cash flow | -$-204.88M | -$-134.68M | -$-70.23M | -$-59.6M | -$-65.55M |
| Capital expenditure | -$-12.01M | -$-1.29M | -$-6.09M | -$-3.71M | -$-1.19M |
| Free cash flow | -$-216.89M | -$-135.97M | -$-76.32M | -$-63.32M | -$-66.74M |
Line items
Line items
Line items
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
- CEO
- Pravin U. Dugel
- Employees
- 325
- Beta
- 0.88
Explore
Frequently asked questions
What is the intrinsic value of Ocular Therapeutix, Inc. (OCUL)?
Ocular Therapeutix, Inc. (OCUL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is OCUL undervalued?
OCUL trades at a price of $5.57 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.